Invizyne Technologies (IZTC) Competitors $11.00 0.00 (0.00%) As of 04/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. ITOS, AQST, MNPR, TSVT, SLDB, SEPN, CMPX, AVIR, ACB, and ATXSShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include iTeos Therapeutics (ITOS), Aquestive Therapeutics (AQST), Monopar Therapeutics (MNPR), 2seventy bio (TSVT), Solid Biosciences (SLDB), Septerna (SEPN), Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Aurora Cannabis (ACB), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. iTeos Therapeutics Aquestive Therapeutics Monopar Therapeutics 2seventy bio Solid Biosciences Septerna Compass Therapeutics Atea Pharmaceuticals Aurora Cannabis Astria Therapeutics iTeos Therapeutics (NASDAQ:ITOS) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Does the media prefer ITOS or IZTC? In the previous week, iTeos Therapeutics had 8 more articles in the media than Invizyne Technologies. MarketBeat recorded 8 mentions for iTeos Therapeutics and 0 mentions for Invizyne Technologies. iTeos Therapeutics' average media sentiment score of 0.74 beat Invizyne Technologies' score of 0.00 indicating that iTeos Therapeutics is being referred to more favorably in the media. Company Overall Sentiment iTeos Therapeutics Positive Invizyne Technologies Neutral Does the MarketBeat Community prefer ITOS or IZTC? iTeos Therapeutics received 47 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformiTeos TherapeuticsOutperform Votes4781.03% Underperform Votes1118.97%Invizyne TechnologiesN/AN/A Is ITOS or IZTC more profitable? Invizyne Technologies' return on equity of 0.00% beat iTeos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets iTeos TherapeuticsN/A -20.11% -17.50% Invizyne Technologies N/A N/A N/A Which has preferable valuation and earnings, ITOS or IZTC? Invizyne Technologies has lower revenue, but higher earnings than iTeos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiTeos Therapeutics$35M7.91-$112.64M-$3.31-2.19Invizyne TechnologiesN/AN/AN/AN/AN/A Do analysts rate ITOS or IZTC? iTeos Therapeutics currently has a consensus price target of $25.50, suggesting a potential upside of 251.72%. Given iTeos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe iTeos Therapeutics is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iTeos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of ITOS or IZTC? 97.2% of iTeos Therapeutics shares are held by institutional investors. 12.5% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryiTeos Therapeutics beats Invizyne Technologies on 9 of the 11 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.77M$3.00B$5.56B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E RatioN/A30.4222.4818.48Price / SalesN/A498.92395.93103.60Price / CashN/A168.6838.1834.62Price / BookN/A3.206.774.25Net IncomeN/A-$72.35M$3.22B$248.23M7 Day Performance-18.70%1.46%1.47%0.89%1 Month Performance5.26%8.79%3.99%3.53%1 Year PerformanceN/A-22.36%16.15%5.08% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$11.00flatN/AN/A$68.77MN/A0.00N/AGap UpITOSiTeos Therapeutics2.0936 of 5 stars$6.99+5.6%$25.75+268.4%-32.5%$265.95M$35M-2.2190Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageAQSTAquestive Therapeutics1.6662 of 5 stars$2.70+4.5%$10.67+295.8%-13.1%$265.47M$57.56M-5.97160Upcoming EarningsNews CoveragePositive NewsMNPRMonopar Therapeutics2.8731 of 5 stars$43.36+1.5%$55.33+27.6%+1,167.1%$265.06MN/A-22.0110Upcoming EarningsNews CoverageGap DownTSVT2seventy bio1.7601 of 5 stars$4.99-0.1%$5.60+12.3%+9.4%$260.91M$37.86M-2.68440Short Interest ↑News CoverageSLDBSolid Biosciences3.9803 of 5 stars$3.35+10.6%$15.67+367.7%-62.7%$259.21M$8.09M-1.10100SEPNSepterna2.2586 of 5 stars$5.80-1.2%$33.00+469.1%N/A$257.28M$1.08M0.00N/ANews CoveragePositive NewsCMPXCompass Therapeutics3.3905 of 5 stars$1.84+3.1%$13.38+628.9%+29.2%$253.89M$850,000.00-4.9620Analyst ForecastShort Interest ↑Analyst RevisionAVIRAtea Pharmaceuticals3.1648 of 5 stars$2.89+0.9%$6.00+108.0%-20.3%$245.88MN/A-1.3970Positive NewsACBAurora Cannabis0.6363 of 5 stars$4.29+2.0%N/A-49.7%$240.99M$320.81M85.761,340News CoverageATXSAstria Therapeutics2.5439 of 5 stars$4.30+4.6%$26.60+518.6%-43.8%$240.41MN/A-2.0430Upcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies iTeos Therapeutics Alternatives Aquestive Therapeutics Alternatives Monopar Therapeutics Alternatives 2seventy bio Alternatives Solid Biosciences Alternatives Septerna Alternatives Compass Therapeutics Alternatives Atea Pharmaceuticals Alternatives Aurora Cannabis Alternatives Astria Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IZTC Stock Free IZTC Stock Alerts